X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Press Statements

World’s Largest Virtual Pharma Expo Agenda Unveiled:

Content Team by Content Team
5th September 2020
in Press Statements
World's Largest Virtual Pharma Expo Agenda Unveiled:

CPhI Festival of Pharma, the world’s largest ever virtual pharma expo, unveils its ground-breaking two-week long agenda. The newly launched and rapidly created virtual event will provide the global pharma community with a vital platform to meet and exchange ideas – at a time when the industry is still adapting to remote ways of working.

The CPhI Festival of Pharma will see global industry heavyweights join forces with more than 20,000 attendees, in what will be a first of its kind virtual pharma gathering designed to meet the needs of the industry in 2021 and beyond.

Amongst more than 50 different content sessions, Dr. Scott Gottlieb – Former FDA Commissioner – will use his keynote platform to implore the industry on continuing its efforts towards combining record innovation with affordable healthcare. His seminal talk will explore how the industry can use this moment to implement more sustainable models, increased patient access, and look ahead at how alternative payment models will improve future healthcare delivery.

In another landmark address, Adrian van den Hoven, Director General, Medicines for Europe will explore the very timely question of how lessons learnt from the COVID-19 pandemic will affect the commission’s new strategy for pharmaceutical policy. Outcomes from which will shape the direction of policy decisions in an ongoing update of pharmaceutical legislation, and therefore, opportunities and challenges ahead for manufacturers operating both within and outside Europe.

Speaking on the aims of Festival of Pharma, Tara Dougal, head of content at CPhI Festival of Pharma, added: “It’s vital in this moment that we empower global pharma with insights and learning in a rapidly evolving global landscape. But of course, global travel restrictions have limited in-person events, so the need for a virtual platform with a holistic perspective has never been greater. To realise our aspirations, we are running the event across two weeks so that we can cover everything from drug discovery and APIs, through to pricing, vaccine development and future technologies like 3D-printed dosages, AI and cell and gene therapies. The great strength of CPhI is that we truly bring everyone together and our content reflects this”.

Gil Roth, another industry pioneer as the founder of the PBOA, will apply his forward-looking perspectives in a keynote on ‘the future of drug manufacturing’. This session will address the current outlook for the CDMO sector, geopolitics and onshoring as well as the lasting legacy COVID may have on pharma supply chains, clinical trials and inspections.

One of the most recent supply side contingencies government and industry has sought to mitigate against is a reliance on international API sources. In a panel discussion, experts will explore what the future of API production will look like, and how the duality of a growing domestic industry will play out against macro changes for hybrid international sourcing models.

Another key issue in a post-COVID working environment is how companies can maintain productivity in remote settings, while continuing to ensure the welfare of their workforces. CPhI is aiming to lead pharma industry efforts and will run a series of ground-breaking sessions entitled Wellbeing at Work covering everything from ‘anxiety’ and ‘brain training’ to getting ‘better sleep’, ‘resilience at work’ and ‘training managers in a digital era’.

Microsoft’s National Director US Life Sciences Industry, Dave Meyers, will present his keynote vision on new collaborations between tech and pharma. Cross-sector collaborations will bring about vast improvements in patient engagement and real-world value, with new immersive patient experiences, personalised communications and real-time care.

“We have designed the content to be incredibly varied and will feature a range of formats from webinars, panel discussions, and podcasts to traditional media interviews, White Papers and unique market insights. The latter will run in the second week and mirror our traditional World of Pharma podiums with market data on India, Japan and the United States,” added Dougal.

The Festival will also include a dedicated Women in Leadership Forum – featuring talks by female CEOs of pharma innovators – and a patient centricity session led by a patient advocacy group. Recognising the industry’s stellar efforts to rapidly develop new solutions in response to COVID-19, there will be a Special COVID Innovation Award. Finally, the eagerly anticipated and hotly contested CPhI Pharma Awards will return with a dedicated virtual ceremony, but this year will also include a live webinar for finalists to pitch details of their entries and innovations. Winners will be unveiled across 15 categories covering every aspect of the pharmaceutical industry and supply chain.

About CPhI

CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, South East Asia, North America, and the Middle East and Africa. Co-locating with ICSE for contract services; P-MEC for machinery, equipment & technology; InnoPack for pharmaceutical packaging; bioLIVE for biopharma; Finished Dosage Formulation for every aspect of the finished dosage supply chain; and NEX for natural extract products, applications and solutions.

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.

Previous Post

Q BioMed Initiates GMP Production of Novel COVID-19 Therapeutic

Next Post

Glatt Selected for GMP Biorefinery Engineering Project by NSTDA in Thailand

Related Posts

Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Press Statements

APM Steam Highlights Comprehensive HVAC Insulation Services for Biopharmaceutical and Pharmaceutical Facilities

19th April 2025
Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Drug Development

Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

4th March 2025
Drug Development

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

4th March 2025
Next Post
Glatt Selected for GMP Biorefinery Engineering Project by NSTDA in Thailand

Glatt Selected for GMP Biorefinery Engineering Project by NSTDA in Thailand

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In